Global InformationBioNTech information
 | |
 Headquarters in Mainz | |
| Company type | Public |
|---|---|
Traded as | Nasdaq: BNTX |
| ISIN | US09075V1026 |
| Industry | Biotechnology |
| Founded | 2008 |
| Founders |
|
| Headquarters | Mainz , Germany |
Number of locations | 8 (2022) |
Area served | Worldwide |
Key people |
|
| Products | BNT162b2 |
| Services | Immunotherapy |
| Revenue |  €3.819 billion (2023) |
Operating income | €690.4 million (2023) |
Net income | €930.3 million (2023) |
| Total assets | €23.01 billion (2023) |
| Total equity |  €20.25 billion (2023) |
Number of employees | 6,133 (2023) |
| Website | biontech |
| Footnotes / references Biontech FY 2023 report[1] | |
BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek[2] short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.[3]
In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which at the time offered a 91% efficacy[4] in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine.[5] On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the United Kingdom.[6][7] It was the first mRNA vaccine ever authorized. Some days later the vaccine also received an emergency approval in the United States,[8] Canada[9] and Switzerland.[10] On 21 December 2020, the European Commission approved BioNTech/Pfizer's coronavirus vaccine in accordance with the positive recommendation of the European Medicines Agency (EMA).[11]
- ^ "BioNTech 2023 Annual Report (Form 20-F)". U.S. Securities and Exchange Commission. 20 March 2024. Retrieved 24 June 2023.
- ^ "BioNTech CEO on vaccine progress with Pfizer – YouTube". Retrieved 14 June 2021 – via YouTube.
- ^ BioNTech SE (9 September 2019), Form F-1, U.S. Securities and Exchange Commission, archived from the original on 14 February 2021, retrieved 23 September 2020
- ^ Commissioner, Office of the (23 August 2021). "FDA Approves First COVID-19 Vaccine". FDA. Retrieved 3 November 2021.
- ^ Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020: FDA Briefing Document – Pfizer-BioNTech COVID-19 Vaccine (Report). Retrieved 4 July 2021.
- ^ Cite error: The named reference
uk12-2awas invoked but never defined (see the help page). - ^ Cite error: The named reference
uk12-2was invoked but never defined (see the help page). - ^ Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions, retrieved 22 December 2020
- ^ Pfizer-BioNTech COVID-19 vaccine: What you should know, 9 December 2020, retrieved 22 December 2020
- ^ Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland, retrieved 22 December 2020
- ^ "Commission approves BioNTech/Pfizer vaccine". Politico. 21 December 2020. Retrieved 22 December 2020.